Clinical Trial Update: Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating loncastuximab tesirine in combination with ibrutinib for diffuse large B-cell lymphoma and mantle cell lymphoma was terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-02-06